Infield Minerals Corp. (TSXV:IN)
Canada · Delayed Price · Currency is CAD | Market Cap | 3.65M +67.0% |
| Revenue (ttm) | n/a |
| Net Income | -302.49K |
| EPS | -0.01 |
| Shares Out | 48.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 55,000 |
| Average Volume | 256,048 |
| Open | 0.0750 |
| Previous Close | n/a |
| Day's Range | 0.0750 - 0.0750 |
| 52-Week Range | 0.0200 - 0.0800 |
| Beta | 1.30 |
| RSI | 67.46 |
| Earnings Date | May 15, 2026 |
About Infield Minerals
Infield Minerals Corp. engages in the acquisition, exploration, and evaluation of mineral resource properties in the United States. The company explores for gold and silver deposits. It also holds 100% interest in the Desperado property that consist of 80 lode mining claims covering an area of approximately 1,650 acres located in the Nye County, Nevada; and Kings Canyon property in the state of Utah. Additionally, it has an option agreement to acquire 100% interest in the Detroit sediment hosted gold property in Utah. Infield Minerals Corp. is ... [Read more]
Financial Performance
Financial StatementsNews
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of InMed Pharmaceuticals, Inc. (NASDAQ: INM)
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and i...
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM)
BALA CYNWYD, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of InMed Pharmaceuticals, Inc. (“InM...
InMed Pharmaceuticals (INM) Soars 170% on Merger with Mentari Therapeutics
InMed Pharmaceuticals (INM) Soars 170% on Merger with Mentari Therapeutics
INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of InMed Pharmaceuticals, Inc. (NASDAQ: INM) and Mentari Therapeutics, Inc. Upon closing of the pr...
InMed Pharmaceuticals Surges 160% On Merger With Mentari; Amends Preferred Investment Options
(RTTNews) - Shares of InMed Pharmaceuticals, Inc. (INM) jumped 160% following news of a definitive merger agreement with privately held Mentari Therapeutics, Inc., a biotechnology company developing t...
InMed Pharmaceuticals (INM) Merges with Mentari Therapeutics for Migraine Treatment Development
InMed Pharmaceuticals (INM) Merges with Mentari Therapeutics for Migraine Treatment Development
InMed Pharmaceuticals, Mentari Therapeutics To Merge
(RTTNews) - InMed Pharmaceuticals (INM) has entered into a definitive merger agreement for an all-stock transaction with Mentari Therapeutics, a privately-held biotechnology company developing therapi...
InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies
Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies Concurrent oversubs...
InMed Pharmaceuticals Amends Preferred Investment Options
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprie...
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propriet...
InMed Pharmaceuticals Amends Preferred Investment Options
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propr...
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifyin...
InMed Pharmaceuticals (INM) Advances Alzheimer's Research with New Preclinical Data
InMed Pharmaceuticals (INM) Advances Alzheimer's Research with New Preclinical Data
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical Trials Consistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimen...
InMed Pharmaceuticals (INM) Sets 2026 Development Goals
InMed Pharmaceuticals (INM) Sets 2026 Development Goals
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling Activities Targeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027 Vanc...
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of diseas...
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - February 11, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing...
InMed Announces Results of 2025 Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...
InMed Provides Update on BayMedica Commercial Business
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...
Why Nvidia Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
Shares of NVIDIA Corp (NASDAQ: NVDA) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and issued a strong revenue forecast for the cu...
What's Driving InMed's (INM) 22% After-Hours Surge?
InMed Pharmaceuticals Inc. (NASDAQ: INM) shares rose 21.98% in after-hours trading Wednesday, reaching $1.50. Check out the current price of INM stock here . The stock closed Wednesday's regular sess...
InMed Pharmaceuticals (INM) Achieves Milestone with INM-901 Study Success
InMed Pharmaceuticals (INM) Achieves Milestone with INM-901 Study Success
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901
Data demonstrate a favorable bioavailability profile of INM-901 oral formulation Data will support design and planning of first in human clinical trials Preparing for pre-IND meeting with the FDA Vanc...
InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing ...